Back to Search
Start Over
Engineered Cell-Derived Microparticles Bi 2 Se 3 /DOX@MPs for Imaging Guided Synergistic Photothermal/Low-Dose Chemotherapy of Cancer.
- Source :
-
Advanced science (Weinheim, Baden-Wurttemberg, Germany) [Adv Sci (Weinh)] 2019 Dec 12; Vol. 7 (3), pp. 1901293. Date of Electronic Publication: 2019 Dec 12 (Print Publication: 2020). - Publication Year :
- 2019
-
Abstract
- Cell-derived microparticles, which are recognized as nanosized phospholipid bilayer membrane vesicles, have exhibited great potential to serve as drug delivery systems in cancer therapy. However, for the purpose of comprehensive therapy, microparticles decorated with multiple therapeutic components are needed, but effective engineering strategies are limited and still remain enormous challenges. Herein, Bi <subscript>2</subscript> Se <subscript>3</subscript> nanodots and doxorubicin hydrochloride (DOX) co-embedded tumor cell-derived microparticles (Bi <subscript>2</subscript> Se <subscript>3</subscript> /DOX@MPs) are successfully constructed through ultraviolet light irradiation-induced budding of parent cells which are preloaded with Bi <subscript>2</subscript> Se <subscript>3</subscript> nanodots and DOX via electroporation. The multifunctional microparticles are obtained with high controllability and drug-loading capacity without unfavorable membrane surface destruction, maintaining their excellent intrinsic biological behaviors. Through membrane fusion cellular internalization, Bi <subscript>2</subscript> Se <subscript>3</subscript> /DOX@MPs show enhanced cellular internalization and deepened tumor penetration, resulting in extreme cell damage in vitro without considering endosomal escape. Because of their distinguished photothermal performance and tumor homing target capability, Bi <subscript>2</subscript> Se <subscript>3</subscript> /DOX@MPs exhibit admirable dual-modal imaging capacity and outstanding tumor suppression effect. Under 808 nm laser irradiation, intravenous injection of Bi <subscript>2</subscript> Se <subscript>3</subscript> /DOX@MPs into H22 tumor-bearing mice results in remarkably synergistic antitumor efficacy by combining photothermal therapy with low-dose chemotherapy in vivo. Furthermore, the negligible hemolytic activity, considerable metabolizability, and low systemic toxicity of Bi <subscript>2</subscript> Se <subscript>3</subscript> /DOX@MPs imply their distinguished biocompatibility and great potential for tumor theranostics.<br />Competing Interests: The authors declare no conflict of interest.<br /> (© 2019 The Authors. Published by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim.)
Details
- Language :
- English
- ISSN :
- 2198-3844
- Volume :
- 7
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Advanced science (Weinheim, Baden-Wurttemberg, Germany)
- Publication Type :
- Academic Journal
- Accession number :
- 32042550
- Full Text :
- https://doi.org/10.1002/advs.201901293